COVID-19大流行期间巨细胞动脉炎患者的临床路径:国际视角
本文为国际作者团队的观点文章,反思COVID-19第一波高峰期间巨细胞动脉炎诊疗服务的快速调整,评估挑战并思考未来影响。文章指出疫情暴露了诊断和治疗临床路径的薄弱环节,但也催生了创新解决方案,强调所有专业人员及患者参与重塑临床服务的重要性。
要点
- 巨细胞动脉炎需快速专科评估和治疗以防止不可逆视力丧失。
- 疫情暴露了巨细胞动脉炎诊断和治疗临床路径的薄弱环节。
- 全科医生、外科医生等所有专业人员在诊疗中均发挥重要作用。
核心结论
- COVID-19大流行暴露了巨细胞动脉炎临床路径的薄弱环节,但也催生了创新解决方案。
研究设计与样本
- 本文为国际作者团队撰写的观点文章,反思COVID-19第一波高峰期间巨细胞动脉炎诊疗服务的快速调整。
主要发现
- 疫情导致卫生系统中断,暴露了巨细胞动脉炎诊断和治疗临床路径的薄弱点。
- 疫情期间的应对也产生了创新性解决方案。
- 所有专业人员(包括全科医生和外科医生)在治疗这些患者中的重要作用已变得明显。
临床怎么用
- 巨细胞动脉炎表现为急症,需要快速专科评估和治疗以预防不可逆视力丧失。
- 患者必须参与临床服务的重塑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Giant cell arteritis, a common primary systemic vasculitis affecting older people, presents acutely as a medical emergency and requires rapid specialist assessment and treatment to prevent irreversible vision loss. Disruption of the health-care system caused by the COVID-19 pandemic exposed weak points in clinical pathways for diagnosis and treatment of giant cell arteritis, but has also permitted innovative solutions. The essential roles played by all professionals, including general practitioners and surgeons, in treating these patients have become evident. Patients must also be involved in the reshaping of clinical services. As an international group of authors involved in the care of patients with giant cell arteritis, we reflect in this Viewpoint on rapid service adaptations during the first peak of COVID-19, evaluate challenges, and consider implications for the future.
引用
- Mackie SL, Brouwer E, Conway R, et al. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatol. 2020. PMID: 33521671. doi:10.1016/S2665-9913(20)30386-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。